Global Day of Action Against Roche’s Inhumanity #RocheGreedKills – Activists Around the World March #ForTobeka

 Posted by on February 7, 2017  Comments Off on Global Day of Action Against Roche’s Inhumanity #RocheGreedKills – Activists Around the World March #ForTobeka
Feb 072017
 

– Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US

– Further campaign activity in India, Russia, Ukraine, Morocco, Zimbabwe

108 organisations endorse a letter to Roche

[TAC Press Release, Link (CC-BY)] Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by Roche across the developed and developing world. Roche’s greed is preventing women from accessing affordable versions of trastuzumab, an essential medicine used in the treatment of breast cancer. Continue reading »

Share
May 092016
 

aust productivity commPrevious infojustice posts about the Australian Government’s Productivity Commission’s Draft Report on Intellectual Property Arrangements have focused on its recommendation that Australia adopt fair use in its copyright law (here and here).  This post highlights the findings regarding the extension of terms for pharmaceutical patents. Australia’s law, in effect since 1999, grants extensions to pharmaceutical firms to make up for time during which the patented drug is awaiting marketing approval.  Total patent term may be extended up to a total of 25 years. Continue reading »

Share

Taiwan Considers Patent Linkage Now to Prepare to Join the TPP in the Future

 Posted by on August 18, 2014  Comments Off on Taiwan Considers Patent Linkage Now to Prepare to Join the TPP in the Future
Aug 182014
 

tw flagInside U.S. Trade reports that Taiwan is taking steps to develop a system of patent linkage, which would prevent generic firms from gaining marketing approval for their products while originator products are still under patent.  The country wants to join the Trans Pacific Partnership at a later date, and it expects that patent linkage will be one of the requirements for countries wishing to acceded to the Agreement.  Continue reading »

Share

UNITAID and the Medicines Patent Pool release the new “Patents and Licences on Antiretrovirals” publication

 Posted by on May 8, 2014  Comments Off on UNITAID and the Medicines Patent Pool release the new “Patents and Licences on Antiretrovirals” publication
May 082014
 

medicines patent pool[Medicines Patent Pool press release, Link, (CC-BY)]The report provides an overview of the patent and licensing status of a select number of antiretroviral medicines in developing countries. Focusing mainly on ARVs recommended by the World Health Organization, the document analyses also data regarding new ARVs that have either recently obtained regulatory approval or are in Phase III clinical trials. Continue reading »

Share

Europe-Wide Resistance Against Syngenta’s Patent on Pepper

 Posted by on February 3, 2014  Comments Off on Europe-Wide Resistance Against Syngenta’s Patent on Pepper
Feb 032014
 

pepperreport-coverPRESS RELEASE: Berne Declaration, Swissaid, Bionext, and No-patents-on-seeds:

Today a broad coalition consisting of 34 NGO’s, farmers’ and breeders’ organisations from 27 European countries filed an opposition to a pepper-patent from Syngenta. The company patented an insect resistance, which they copied from a wild pepper. Such patents are ethically questionable, increase the seed market concentration, hinder innovation, and consequently pose a threat to global food security. While filing the opposition in Munich, a hot pepper soup was served to the employees of the European patent office Continue reading »

Share

Non-SDO Patent Commitments and Pledges

 Posted by on October 17, 2013  Comments Off on Non-SDO Patent Commitments and Pledges
Oct 172013
 

contrerasThere has been a surge of interest lately in commitments to license patents on terms that are “fair, reasonable and non-discriminatory” (FRAND).  The patents at issue in these cases often cover industry standards that were developed in collaborative trade associations known as standards-development organizations (SDOs). But while the principal focus of litigants and regulators in recent years has been on patent commitments made within SDOs, parties have increasingly made voluntary public patent statements and commitments in less formal settings.  Such statements and commitments can take the form of covenants not to sue, promises to license on royalty-free or FRAND terms, or clarifications of previous commitments that have been made.  Continue reading »

Share
Jul 272013
 
Burcu Kilic and Luigi Palombi

Burcu Kilic and Luigi Palombi

[Burcu Kilic and Luigi Palombi]  Over the past few years, patent-eligible subject matter has become one of the hotly debated areas of patent law in several countries. Even in the U.S., the Supreme Court is beginning to express concerns about overly inclusive patent rules that stifle both competition and follow-on innovation.  However, significant confusion persists over the difference between patent eligible subject matter and patentability requirements. Patent eligibility tests have proven quite difficult to apply, often leading to inconsistent and unpredictable results. Continue reading »

Share

Investor–State Arbitration to Challenge Host State Compliance with International IP Treaties?

 Posted by on February 18, 2013  Comments Off on Investor–State Arbitration to Challenge Host State Compliance with International IP Treaties?
Feb 182013
 

lilly[Posted by Henning Grosse Ruse-Khan on the International Economic Law and Policy Blog (CC BY-NC 2.5)]  Last week, Luke Peterson reported that the U.S. based pharma corporation Eli Lilly has put Canada on notice of its intent to submit a claim to arbitration under NAFTA Chapter 11 following the invalidation of some of its patents by Canadian courts (http://www.iareporter.com/articles/20121203_2). The Notice of 7 November 2012 is now available on Andrew Newcombe’s website (http://italaw.com/cases/1625). It reveals an interesting new interface between international IP and investment law. Continue reading »

Share

Patent-less Smartphone Innovation and Global Technology Markets

 Posted by on December 20, 2012  Comments Off on Patent-less Smartphone Innovation and Global Technology Markets
Dec 202012
 

[Cross posted from Patent Progress] This weekend I attended the Second Global Congress on IP and the Public Interest held in Rio de Janeiro.  The Congress is intended to draw attention to the often-overlooked public interest aspects of global intellectual property policy and to offer an organized counterpoint to the so-called “maximalist” IP agenda.  Last year’s Congress, held in Washington, DC, produced an ambitious policy framework and “positive” public interest agenda titled the Washington Declaration on Intellectual Property and the Public Interest.  While much of the Congress focused on issues of knowledge dissemination, copyright protection and Internet freedom, a few sessions were devoted to patent issues.  Of these, most addressed the longstanding debate surrounding access to medicines and health innovation in the developing world, with special attention to the recent compulsory licensing of pharmaceutical patents in Indonesia and India.

But for readers of Patent Progress, another recent development in India may prove to be the most interesting.  I am referring to a presentation made by Sunil Abraham, Executive Director of Bangalore’s Centre for Internet & Society.  During his 15-minute presentation, Mr. Abraham showed a dozen different smartphones currently on the market in India, most with price points in the range of US $20-$40, and with a range of features that we can only dream about in the West.   Continue reading »

Share

Department of Commerce Seeks Comments on “Feasibility of Placing Economically Significant Patents Under a Secrecy Order”

 Posted by on April 30, 2012  Comments Off on Department of Commerce Seeks Comments on “Feasibility of Placing Economically Significant Patents Under a Secrecy Order”
Apr 302012
 

[Federal Register, vol 77, no. 77]:  Pursuant to a request from Congress, the United States Patent and Trademark Office (USPTO) is seeking comments as to whether the United States should identify and bar from publication and issuance certain patent applications as detrimental to the nation’s economic security. The USPTO is also seeking comments on the desirability of changes to the existing procedures for reviewing applications that might be detrimental to national security. Those wishing to submit written comments should submit those comments for consideration by June 19, 2012.

Click here for the full federal register notice.

Share

Indian High Court to Hear Novartis Patent Case

 Posted by on March 26, 2012  Comments Off on Indian High Court to Hear Novartis Patent Case
Mar 262012
 

On Wednesday, the Indian Supreme Court will hear arguments in Novartis’ challenge to India’s patent law.  In 2006, the Indian Patent Office rejected Novartis’ patent application for the cancer drug Glivec (imatinib mesylate), saying that the drug was a new salt formulation of a known drug, and therefore unpatentable under Indian Law.  Section 3(d) of the Indian Patents Act specifies that patents cannot be granted for “the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance…”  Novartis has asked that court to endorse a broad interpretation of the word “efficacy” that would include its product. Continue reading »

Share
Dec 222011
 

The Brazilian Instituto nacional da Propriedade Industrial announced it will fast track its decision on whether or not to grant patents on the heat-stablized versions of lopinavir+ritonavir (brand names: Kaletra, Aluvia) and ritonavir (Norvir). Both drugs are important antiretroviral drugs recommended by the World Health Organization for HIV/AIDS treatment in resource-poor settings.  If the follow on patents are granted, they will not expire until 2024. Continue reading »

Share